(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 3.33% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Gilead Sciences's revenue in 2025 is $29,087,000,000.On average, 31 Wall Street analysts forecast GILD's revenue for 2025 to be $36,968,530,726,531, with the lowest GILD revenue forecast at $34,778,731,191,936, and the highest GILD revenue forecast at $38,714,166,956,092. On average, 31 Wall Street analysts forecast GILD's revenue for 2026 to be $38,066,532,192,886, with the lowest GILD revenue forecast at $34,923,890,707,827, and the highest GILD revenue forecast at $40,709,179,789,876.
In 2027, GILD is forecast to generate $39,985,863,569,667 in revenue, with the lowest revenue forecast at $36,962,327,328,416 and the highest revenue forecast at $43,655,793,894,501.